epicur

MARCH 12, 2024

Epicur Pharma’s Advisory Council member Ann Donoghue, DVM, MS shares her personal perspective on the important relationship between veterinary oncology and compounded medications used in chemotherapy treatments. Many of the presentations discussed the chemotherapies available to treat dogs.

Compounding 52

Compounding Chemotherapy Compounding Pharmacies Labelling 52

pharmaphorum

MARCH 8, 2021

AZ is seeking to use Lynparza in patients who had also been previously treated with the chemotherapy drug docetaxel, but NICE has concluded that the application failed to provide evidence of the PARP inhibitor’s value compared to standard therapy.

Chemotherapy 98

Chemotherapy Labelling 98

pharmaphorum

FEBRUARY 8, 2021

Breyanzi has however been cleared with a similar black box warning on its label for neurotoxicity and cytokine release syndrome (CRS) as Novartis and Gilead/Kite’s therapies. At the moment there are limited fallback options for patients whose lymphoma progresses despite first line chemotherapy and anti-CD20 treatment.

Chemotherapy 111

Chemotherapy Labelling 111

pharmaphorum

APRIL 30, 2021

Merck’s drug has been approved for this use since 2017, but failed to show a statistically significant improvement over third-line chemotherapy in either of two confirmatory trials – KEYNOTE-061 and KEYNOTE-062.

Chemotherapy 59

Chemotherapy Labelling 59

European Pharmaceutical Review

OCTOBER 19, 2023

How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? There is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies. cited 2023Oct].

Chemotherapy 105

Chemotherapy Compounding Immunization Immunity 105

pharmaphorum

AUGUST 24, 2021

Novartis’ CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn’t added to its label since. Standard care was salvage chemotherapy followed in eligible patients by high-dose chemotherapy and a stem cell transplant.

Chemotherapy 52

Chemotherapy Labelling 52

European Pharmaceutical Review

JULY 5, 2022

The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. Benefits of daily oral chemotherapy over IV.

Chemotherapy 104

Chemotherapy Dosage Labelling Compounding 104